Newamsterdam Pharma
Clinical trials sponsored by Newamsterdam Pharma, explained in plain language.
-
New combo aims to crush 'Bad' cholesterol particle that other drugs miss
Disease control Recruiting nowThis 16-week study tests whether a daily pill (obicetrapib) plus a twice-monthly shot (evolocumab, sold as Repatha) can lower a fatty particle called lipoprotein(a) that raises heart disease risk. About 69 adults with mildly high cholesterol and elevated Lp(a) will take the pill …
Phase: PHASE2 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill combo aims to slash cholesterol in High-Risk patients
Disease control Recruiting nowThis Phase 3 study tests whether a daily pill combining obicetrapib and ezetimibe, or obicetrapib alone, can lower LDL (bad) cholesterol more than placebo in 300 people with type 2 diabetes or metabolic syndrome. Participants continue their standard cholesterol medications. The m…
Phase: PHASE3 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Healthy volunteers sought to test if experimental drug boosts antioxidant absorption.
Knowledge-focused Recruiting nowThis study tests whether the experimental drug obicetrapib can increase the amount of antioxidants (like lutein and vitamin E) in the blood and eyes of healthy people. One hundred volunteers will take either the drug or a placebo daily for 4 months, with regular blood draws and e…
Phase: PHASE2 • Sponsor: NewAmsterdam Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC